Hims & Hers Health (NYSE:HIMS) shares exploded 33% at 8:10 am in the premarket trading today after announcing a major expansion of its telehealth weight-loss offerings through a new direct partnership with Novo Nordisk's (NYSE:NVO) NovoCare Pharmacy. Patients can now access authentic, FDA-approved Wegovy through Hims & Hers, LifeMD, and Ro, using a streamlined self-pay model priced at $499 per month. With supply fully restored, the move positions Hims & Hers to capitalize on soaring demand as weight-loss treatments reshape the healthcare landscape.
Wegovy, first approved in 2021, has rapidly become a game-changer for chronic weight management, offering the first weekly GLP-1 therapy for obesity. Its value grew even stronger in 2024 when the FDA expanded its label to cover cardiovascular risk reduction, helping it reach nearly 1.5 million patients across the U.S. By tapping into Novo Nordisk's direct distribution model, Hims & Hers is not only expanding its footprint in one of the fastest-growing markets but also reinforcing its brand as a trusted gateway to premium, FDA-approved treatments.
As more than 100 million Americans live with obesity, Hims & Hers is aggressively positioning itself at the intersection of telehealth and chronic disease management. This partnership enables faster access, direct-to-doorstep delivery, and lower costs for patients all while strengthening Hims & Hers' reputation as a major player in the healthcare space. With today's move, the company is stepping into a higher-growth lane just as traditional healthcare delivery struggles to keep pace with evolving patient expectations.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。